Akari Therapeutics plc insider trading

Every open-market purchase and sale by Akari Therapeutics plc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Akari Therapeutics plc’s insiders pay?

From March 24, 2014 to August 29, 2025, 5 insiders reported 10 open-market purchases and 0 sales not made under a pre-set plan in Akari Therapeutics plc. Twelve months after each purchase was reported, the shares were −98.9% against the S&P 500 on average (median −100.9%), over 7 purchases with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 25, 2014 into $436 by November 2, 2026, −22.0% a year. It held shares 16% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $16,857 (+4.2% a year), and held throughout $50,020 (+13.7%).

Copying Akari Therapeutics plc's insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Akari Therapeutics plc's insiders from March 25, 2014, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 16% of the time.

Akari Therapeutics plc: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	12 months after their sales	Latest report
Gaslightwala Abizer	CEO	3	—	—	—	August 29, 2025
Sabby Management, LLC	10% owner	3	−101.7% (3)	0%	—	April 8, 2014
Sabby Healthcare Master Fund, Ltd.	10% owner	2	−100.8% (2)	0%	—	April 17, 2014
Cohen Mark S	Director	1	−83.7% (1)	0%	—	September 22, 2015
Mintz Hal	10% owner	1	−102.1% (1)	0%	—	April 11, 2014

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Akari Therapeutics plc

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Akari Therapeutics plc in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −19.3% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
March 31, 2014	2 buying	−9.6%	−19.3%	−100.8%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Akari Therapeutics plc · Funds · Politicians